Photo credit: CC0 Public Domain
Based on their experience and expertise in telemedicine, collaborative care models, substance use disorders, depression, and health information technology, Indiana University Medical School and the Regenstrief Institute faculty received a $ 3.9 million collaboration over a four year period with scientists from the Kaiser Permanente Washington Health Research Institute granted on a study to optimize treatment for opioid use disorder.
You will test whether a scalable, telemedicine-provided collaborative care model can motivate primary care patients who are dependent on opioids and also suffer from depression to become more committed to evidence-based treatments for pain and opioid use disorders while improving their symptoms of depression .
The MI-CARE study (acronym for Individualized Care: Assessment and Recovery through Commitment) is supported by the National Institute of Health’s National Institute of Mental Health (NIH) through The Helping to End Addiction Long-Term, or NIH HEAL Initiative national opioid crisis.
“A patient who comes to the doctor’s office with a heart problem does not usually need to be motivated to follow a treatment regimen, but with mental health problems, in part because of the stigma associated with these disorders, patients often need support to become involved and motivated to adhere to medication and other recommendations from their family doctor, “said Regenstrief Institute research scientist and professor of medicine to the Chancellor of the IU School of Medicine, Dr. Kurt Kroenke, Co-Principal Investigator for the Indiana site. “In studies we conducted during the COVID-19 pandemic and in real-life situations, telehealth has shown real potential for supporting patients and families. The MI-CARE study is linked to the value of telehealth Use of collaborative care valued in the fight against opioid. “
Opioid use and depression often occur simultaneously and are mutually reinforcing. Motivating people with opioid use disorder and depression to seek and continue to use evidence-based treatments for their conditions has been an unmet challenge. These patients suffer from multiple problems and need pragmatic clinical approaches that work.
The research scientist of the Regenstrief Institute, Dr. Kurt Kroenke, is Co-Principal Investigator at the Indiana site for More Individual Nursing: Assessment and Recovery through Engagement. The study will test whether a scalable, collaborative care model provided by telemedicine can motivate primary care patients who are dependent on opioids and who also suffer from depression to become more committed to evidence-based treatments for pain and opioid use disorders while reducing symptoms of depression to improve. Photo credit: Regenstrief Institute
“Most physicians are called to medicine out of a desire to alleviate human suffering. For decades, prescribing opioid drugs to treat chronic pain has been viewed as a means of relieving the ailment. Unfortunately, this well-intentioned practice has become an epidemic of Opioid addiction and overdose contributed deaths, “said Regenstrief Institute-affiliated scientist and assistant professor of psychiatry at the IU School of Medicine, Michael Bushey, Ph.D., principal researcher at the Indianapolis site. “Providing primary care opioid use disorder services is the fastest way to reach most patients. However, we must provide our primary care providers with the resources they need to be successful. We hope MI-CARE does a lot more patients can take in primary care to gain access to evidence-based treatments for opioid use disorder and depression. “
At the Indiana site of the randomized, controlled MI-CARE study, 400 people with opioid addiction and depression are being studied. Half of them are cared for by their general practitioners as usual. The other 200 will be contacted by phone by a behavioral nurse and will offer the opportunity to receive a nurse-supported telehealth program in collaboration with their primary care team. This typically includes evidence-based drugs for opioid disorders such as buprenorphine or long-acting naltrexone, as well as treatments to improve their depression.
Results for both the treatment group and the usual care groups are obtained from the patient’s electronic health records, which contain clinical, laboratory and other information. The research scientists at the Regenstrief Institute, Dr. David Haggstrom, and Dr. med. Titus Schleyer, DMD, leads the data team for the study site in Indiana.
“We will use cutting-edge data science tools developed at the Regenstrief Institute to measure opioid use and depression care with high accuracy,” said Dr. Haggstrom, interim director of the Regenstrief Center for Health Services Research.
Caring for complex patients, such as B. Patients with concurrent opioid use disorder and depression can be challenging. Although treating opioid use disorder in primary care (where most adults get their medical care) is a public health priority, clinical experience and resources in this area lag behind depression, which in turn lags behind treating physical ailments.
One of the goals of the MI-CARE study is to determine whether the promises of telemedicine and coordinated care can help GPs provide the care that opioid users with depression so clearly need.
Frontline caregivers were given tools to play a greater role in the fight against opioid abuse. These are provided by the Regenstrief Institute
Quote: Using Telecare to Motivate Depressed People Using Opioids (2020, October 27), accessed December 8, 2020 from https://medicalxpress.com/news/2020-10-telecare-depressed-individuals-opioids -treatment.html
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.
Comments are closed.